Page last updated: 2024-08-24

1,2-distearoyllecithin and Local Neoplasm Recurrence

1,2-distearoyllecithin has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A1
Chen, CA; Hsiao, SM; Hsieh, CY; Lin, HH; Wei, LH1

Trials

1 trial(s) available for 1,2-distearoyllecithin and Local Neoplasm Recurrence

ArticleYear
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
    Gynecologic oncology, 2009, Volume: 112, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols

2009

Other Studies

1 other study(ies) available for 1,2-distearoyllecithin and Local Neoplasm Recurrence

ArticleYear
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2013